Hamid Ghaznavi

Dr. Hamid Ghaznavi


Research Focus & Metrics

Academic Career Length

8Years (2019-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
10 September 2025 in Cancer Medicine
Verified
Journal Article
Open access
SHSomayyeh Hormaty
Somayyeh Hormaty
ASAnwar Nather Seiwan
Anwar Nather Seiwan
BRBushra H. Rasheed
Bushra H. Rasheed
HPHanieh Parvaz
Hanieh Parvaz
AGAli Gharahzadeh
Ali Gharahzadeh
HGHamid Ghaznavi
Hamid Ghaznavi
Background: Ovarian cancer (OC) remains the most lethal gynecological malignancy, largely due to its late‐stage diagnosis and nonspecific early symptoms. Advances in biomarker identification and machine learning offer promising avenues for improving early detection and prognosis. This review evaluates the role of biomarker‐driven ML models in enhancing the early detection, risk stratification, and treatment planning of OC. Methods: We analyzed literature spanning clinical, biomarker, and ML studies, emphasizing key diagnostic and prognostic biomarkers (e.g., CA‐125, HE4) and ML techniques (e.g., Random Forest, XGBoost, Neural Networks). The review synthesizes findings from 17 investigations that integrate multi‐modal data, including tumor markers, inflammatory, metabolic, and hematologic parameters, to assess ML model performance. Findings: Biomarker‐driven ML models significantly outperform traditional statistical methods, achieving AUC values exceeding 0.90 in diagnosing OC and distinguishing malignant from benign tumors. Ensemble methods (e.g., Random Forest, XGBoost) and deep learning approaches (e.g., RNNs) excel in classification accuracy (up to 99.82%), survival prediction (AUC up to 0.866), and treatment response forecasting. Combining CA‐125 and HE4 with additional markers like CRP and NLR enhances specificity and sensitivity. However, limitations such as small sample sizes, lack of external validation, and exclusion of imaging/genomic data hinder clinical adoption. Conclusion: Biomarker‐driven ML represents a transformative approach for OC management, improving diagnostic precision and personalized care. Future research should prioritize multi‐center validation, multi‐omics integration, and explainable AI to overcome current challenges and enable real‐world implementation, potentially reducing OC mortality through earlier detection and optimized treatment.

13 October 2025 in Journal of Physics D: Applied Physics
Verified
Journal Article
Open access
HGHamid Ghaznavi
Hamid Ghaznavi
MRMohammad Rezaee
Mohammad Rezaee
FRFrancisco Reynoso
Francisco Reynoso
ADArash Darafsheh
Arash Darafsheh
Radiation therapy (RT) employs ionizing radiation to kill cancerous cells. However, delivering radiation to tumors, typically embedded within normal tissues, inevitably exposes healthy organs to radiation, leading to collateral damage. This creates a tradeoff between the tumor control probability and normal tissue complication probability, ultimately limiting the dose that can be safely administered. While highly conformal RT techniques have improved tumor targeting and treatment efficacy, they remain inadequate for treating large and radioresistant tumors, pointing out the need for alternative strategies. Spatially fractionated RT, ultra-high dose rate RT, and nanoparticle-enhanced RT are emerging techniques with promise in enhancing tumor control while minimizing normal tissue toxicity. Successful clinical translation of these advanced techniques requires cross-disciplinary efforts aimed at technological innovation, a deeper understanding of the underlying radiobiological mechanisms, and the development of early-phase clinical trials. This paper provides an overview of these techniques and their associated challenges and opportunities.

1 January 2022 in Journal of Medical Signals & Sensors
Verified
Journal Article
Open access
PDF file
HGHamid Ghaznavi
Hamid Ghaznavi
Sadegh GhaderiSadegh Ghaderi
Sadegh Ghaderi
KGKayvan Ghaderi
Kayvan Ghaderi
Nowadays, magnetic resonance imaging (MRI) has a high ability to distinguish between soft tissues because of high spatial resolution. Image processing is extensively used to extract clinical data from imaging modalities. In the medical image processing field, the knee's cyst (especially Baker) segmentation is one of the novel research areas. There are different methods for image segmentation. In this paper, the mathematical operation of the watershed algorithm is utilized by MATLAB software based on marker-controlled watershed segmentation for the detection of Baker's cyst in the knee's joint MRI sagittal and axial T2-weighted images. The performance of this algorithm was investigated, and the results showed that in a short time Baker's cyst can be clearly extracted from original images in axial and sagittal planes. The marker-controlled watershed segmentation was able to detect Baker's cyst reliable and can save time and current cost, especially in the absence of specialists it can help us for the easier diagnosis of MRI pathologies.

11 March 2025 in Medicine Advances
Verified
Journal Article
Open access
NANegar Abdi
Negar Abdi
MAMiad Alsulami
Miad Alsulami
HGHamid Ghaznavi
Hamid Ghaznavi
PET/CT has become the reference standard imaging modality for diagnosing prostate cancer because of its ability to target prostate‐specific membrane antigen (PSMA), a protein specific to prostate cells. [68Ga]Ga‐PSMA‐11 was a major advance, but limitations such as a short lifespan and image blurring led to the introduction of [18F]PSMA‐1007, which offers advantages such as a longer lifespan and clearer images. This study aimed to compare the effectiveness of [18F]PSMA‐1007 and [68Ga]Ga‐PSMA‐11 in the detection and staging of recurrent prostate cancer because there is currently insufficient evidence to conclude that one PSMA‐radiotracer is better than the other. Both 68Ga and 18F‐labeled PSMA‐radiotracers have similar detection rates in patients. Therefore, more investigation is required to authoritatively conclude which radiotracer results in optimal performance for diagnosing prostate cancer lesions on PET/CT. In this narrative review, we focus on comparing the effectiveness of [18F]PSMA‐1007 with that of [68Ga]Ga‐PSMA‐11 in the detection of recurrent prostate cancer and determination of its stage. We found that [18F]PSMA‐1007 and [68Ga]Ga‐PSMA‐11 showed similar diagnostic performance, with [18F]PSMA‐1007 having slightly higher sensitivity for primary and metastatic recurrent prostate cancer. However, a lack of statistical significance in the differences between the two radiotracers indicates comparable diagnostic accuracy, enabling their interchangeable use based on availability and cost efficiency.

5 July 2021 in Journal of Cancer Research and Clinical Oncology
Verified
Journal Article
Closed access
PDF file
HGHamid Ghaznavi
Hamid Ghaznavi

24 April 2025 in Physics in Medicine & Biology
Verified
Journal Article
Open access
HGHamid Ghaznavi
Hamid Ghaznavi
BMBorna Maraghechi
Borna Maraghechi
HZHailei Zhang
Hailei Zhang
TZTong Zhu
Tong Zhu
ELEric Laugeman
Eric Laugeman
ADArash Darafsheh
Arash Darafsheh
The fundamental goal in radiation therapy (RT) is to simultaneously maximize tumor cell killing and healthy tissue sparing. Reducing uncertainty margins improves normal tissue sparing, but generally requires advanced techniques. Adaptive RT (ART) is a compelling technique that leverages daily imaging and anatomical information to support reduced margins and to optimize plan quality for each treatment fraction. An especially exciting avenue for ART is proton therapy (PT), which aims to combine daily plan re-optimization with the unique advantages provided by protons, including reduced integral dose and near-zero dose deposition distal to the target along the beam direction. A core component for ART is onboard image guidance, and currently two options are available on proton systems, including cone-beam computed tomography (CBCT) and CT-on-rail (CToR) imaging. While CBCT suffers from poorer image quality compared to CToR imaging, CBCT platforms can be more easily integrated with PT systems and thus may support more streamlined adaptive proton therapy (APT). In this review, we present current status of CBCT application to proton therapy dose evaluation and plan adaptation, including progress, challenges and future directions.